2025-11-15 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the information you provided, presented in an easy-to-read format with initial numerical summaries followed by analysis.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 78.55%
*   **VOO Cumulative Return:** 98.45%
*   **Absolute Divergence:** -19.90% (TGTX is lagging VOO by 19.90% cumulatively)
*   **Divergence Range:** Max: 305.5, Min: -101.0
*   **Relative Divergence:** 20.4 (Indicates the current divergence is in the lower end of its historical range relative to VOO).

**Analysis of Provided Table:**

The provided table gives a look at the rolling 3-year performance of TGTX compared to a benchmark, likely the S&P 500. Here's a breakdown:

*   **CAGR (Compound Annual Growth Rate):**  Highly variable.  Significant growth in 2018-2020 and 2019-2021, but substantial negative growth in 2020-2023, and 2021-2023. Recent positive shift in 2022-2025, and 2023-2025.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant risk and volatility.
*   **Alpha:** Measures outperformance relative to the benchmark.  Positive alpha in periods of strong growth, negative alpha in periods of decline, indicating TGTX's performance is heavily dependent on market conditions and its own specific events.
*   **Beta:** Measures volatility relative to the market.  Beta consistently above 1 suggests TGTX is more volatile than the market. The beta is negative in recent periods, implying the stock is moving in the opposite direction to the market (which is very unlikely).
*   **Cap(B):** This seems to be capitalization in Billions.

**Summary:** TGTX has shown periods of extreme outperformance but also significant underperformance and high volatility. It is a high-risk, high-reward stock.

### 2. Recent Stock Price Movement

*   **Current Price:** 31.0
*   **Previous Close:** 30.96
*   **Change:** 0.13
*   **5-Day Moving Average:** 30.876
*   **20-Day Moving Average:** 33.2207
*   **60-Day Moving Average:** 33.2439

**Analysis:**

The stock price saw a small increase from the previous close, with the current price showing a minor rebound. The price is trading below both the 20-day and 60-day moving averages, suggesting a short-term downward trend. However, the price is slightly above the 5-day moving average, which indicates that the stock price is showing positive movement in the very short term.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 35.74 (Approaching oversold territory)
*   **PPO:** -1.08 (Negative, indicating a potential downtrend)
*   **Hybrid Signal:** Cash_80%_Sell (Suggests a bearish outlook, recommending selling 80% of holdings). MRI associated with the signal is 0.5, indicating this signal is considered risky.
*   **Recent (20-day) Relative Divergence Change:** 0.7 (+) (Indicates short-term upward momentum relative to VOO)
*   **Expected Return:** -111.6% (Significantly negative, suggesting substantial underperformance compared to the S&P 500 over a 2+ year investment horizon.)

**Analysis:** The MRI suggests a medium investment risk, but the hybrid signal and expected return paint a more concerning picture. The negative expected return is a major red flag.

### 4. Recent News & Significant Events

*   **Negative News:** Roche's test results impacting TG Therapeutics negatively. (Investor's Business Daily)
*   **Conference Participation:** TG Therapeutics participating in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire)
*   **Mixed News:** Zack's highlights long-term growth potential, while Simply Wall St. points out margin issues.
*   **Positive News:** TGTX's Q3 earnings and revenues beat estimates and raised 2025 outlook (Zacks). Valuation being explored as growth prospects spark investor interest (Simply Wall St.).

**Analysis:** The news flow is mixed. While there's some positive news regarding earnings and growth potential, the negative news regarding Roche's results is a significant concern.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** Average: 44.29, High: 60.00, Low: 13.00
*   **Recent Rating Changes:** No changes provided

**Analysis:** Analysts, on average, have a "Buy" rating with a significant upside potential based on the average target price. However, the wide range between the high and low target prices indicates considerable uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-11-05 | 2.69 | $0.16B     |
| 2025-08-08 | 0.19 | $0.14B     |
| 2025-05-09 | 0.03 | $0.12B     |
| 2024-11-07 | 0.03 | $0.08B     |
| 2025-11-05 | 0.03 | $0.08B     |

**Analysis:**
The earnings per share (EPS) for the most recent quarter is significantly higher than previous quarters.
The revenue has been steadily increasing over the past few quarters.

### 6. Financial Information:

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

Capital and Profitability:

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $0.61B    | 64.37%   |
| 2025-06-30   | $0.28B    | 10.20%   |
| 2025-03-31   | $0.24B    | 2.13%    |
| 2024-12-31   | $0.22B    | 10.49%   |
| 2024-09-30   | $0.19B    | 2.02%    |

**Analysis:**

*   **Revenue:** Revenue has shown consistent growth over the past year, which is a positive sign.
*   **Profit Margin:** Profit margins are very high and relatively stable, suggesting the company has strong pricing power or efficient cost management.
*   **Equity:** Equity has increased substantially in the most recent quarter, which could be due to positive earnings or capital raising activities.
*   **ROE (Return on Equity):** ROE is exceptionally high in the most recent quarter, indicating efficient use of equity to generate profits.

### 7. Overall Summary

TG Therapeutics presents a mixed picture.

*   **Positives:**
    *   Strong revenue and profit margin growth
    *   Recent Q3 earnings beat and raised outlook
    *   Positive analyst consensus (Buy) with significant upside potential
    *   Recent positive increase in equity
*   **Negatives:**
    *   Historical underperformance relative to the S&P 500 and high volatility.
    *   High maximum drawdown
    *   Negative expected return over a 2+ year horizon.
    *   Recent negative news regarding Roche's test results.
    *   Hybrid signal recommends selling 80% of holdings (bearish outlook).

**Conclusion:**

TGTX is a high-risk investment. While there are positive signs in recent earnings and analyst ratings, the historical volatility, underperformance, and negative expected return warrant caution. The recent negative news could be a significant drag on the stock. A very high-risk profile, the investor need to do their own due diligence.
